...
机译:伊立替康联合输注5-氟尿嘧啶/亚叶酸或卡培他滨加塞来昔布或安慰剂用于转移性结直肠癌患者的一线治疗。 EORTC研究40015
Department of Oncology and Hematology Klinikum Oldenburg Oldenburg Germany;
Department of Oncology Universitair Ziekenhuis Brussel Vrije Universiteit Brussels Belgium;
University Medical Center II Eberhard-Karls-Universität Tübingen Germany;
Department of Medical Oncology National Institute of Oncology Budapest Hungary;
Department of Internal Medicine AZ Groeninghe Campus Sint-Niklaas Kortrijk Belgium;
Onkologischer Schwerpunkt Lerchenfeld Hamburg;
II. Medizinische Abteilung Allgemeines Krankenhaus Altona Hamburg Germany;
Department of Hemato-Oncology Ziekenhuis Netwerk Middelheim Campus Middelheim Antwerpen Belgium;
Onkologische Schwerpunktpraxis Leer Leer Germany;
Department of Gastroenterology Sint-Elisabeth Ziekenhuis Turnhout Belgium;
Department of Oncology and Hematology Universitätsklinikum Hamburg-Eppendorf Hamburg;
Medizinische Klinik III Würzburg;
Medizinische Klinik I Westpfalz-Kinikum Kaiserslautern;
Medical Department Hematology Oncology and Gastroenterology Vivantes Klinkum Spandau Berlin;
Department of Oncology Kliniken Essen-Mitte Essen Germany;
Department of Gastroenterology Chemotherapy Unit Institut Jules Bordet Brussels;
Department of Medical Oncology Universitair Ziekenhuis Antwerpen Edegem;
European Organisation for Research and Treatment of Cancer (EORTC) EORTC Data Center Brussels;
Digestive Oncology Unit University Hospital Gasthuisberg Leuven Belgium;
机译:伊立替康联合输注5-氟尿嘧啶/亚叶酸或卡培他滨加塞来昔布或安慰剂用于转移性结直肠癌患者的一线治疗。 EORTC研究40015。
机译:CAPIRI(卡培他滨,伊立替康)加贝伐单抗与FOLFIRI(亚叶酸,5-氟尿嘧啶,伊立替康)加贝伐单抗的II期随机试验作为一线治疗不可切除的结肠癌(mCRC)患者
机译:一线输注24小时5-氟尿嘧啶/亚叶酸治疗晚期大肠癌失败后,依立替康和卡培他滨作为二线治疗:II期研究。
机译:CAPIRI(卡培他滨伊立替康)加贝伐单抗与FOLFIRI(亚叶酸5-氟尿嘧啶伊立替康)加贝伐单抗的II期随机试验作为不可切除/转移性结直肠癌(mCRC)患者的一线治疗
机译:一线伊立替康联合5-氟尿嘧啶和亚叶酸Mayo的I / II期研究在晚期大肠癌患者中的应用